L-Carnitine
Amino Acid Derivative | Energy & Fat Metabolism
On this page
What is L-Carnitine?
L-Carnitine is a naturally occurring compound the body makes from two amino acids, and it plays a key role in moving fat into cells' energy-producing mitochondria. It's FDA-approved as an injectable medication (Carnitor) for carnitine deficiency and is widely studied for effects on energy metabolism, heart health, and exercise recovery. Research-grade L-Carnitine sold here is intended for laboratory research use only and is not the same product as, and is not a substitute for, an approved prescription medication.
Key terms:
L-Carnitine is a small molecule.
L-Carnitine (levocarnitine) is a naturally occurring amino acid derivative. It carries long-chain fatty acids into mitochondria — the cell's energy factories — for energy production via beta-oxidation. The body makes it from lysine and methionine. It plays critical roles in energy metabolism, particularly in high-energy tissues like heart, brain, and skeletal muscle. It is FDA approved as Carnitor® for primary and secondary carnitine deficiency. Various forms exist: Acetyl-L-Carnitine (ALCAR) for cognitive support, L-Carnitine L-Tartrate (LCLT) for exercise recovery, and Propionyl-L-Carnitine for cardiovascular health. It has been studied extensively — over 200 clinical trials have examined effects on weight management, exercise performance, heart health, cognitive function, and male fertility.
Key research areas
- Maximum bioavailability (100% vs 14-18% oral)
- Rapid onset of action
- Bypasses gut microbiome conversion to TMAO
- Particularly useful for carnitine deficiency states and clinical settings
- Supports fat metabolism and energy production in high-energy tissues
Researched dosing
This table reflects how researchers and clinicians have structured L-Carnitine study and treatment designs — dose ranges from clinical and research settings, presented as reference, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Carnitine-deficiency studies | 50 mg/kg/day | Divided doses or continuous | IV |
| Hemodialysis studies | 10-20 mg/kg | Post-dialysis | IV - Slow push |
| Fat-metabolism and performance studies | 500-1500mg | 1-3x weekly | SubQ or IM |
| Critical-illness studies | Up to 300 mg/kg/day | Divided or continuous | IV - Infusion |
Commonly cycled 12 weeks on, 0+ weeks off.
How it works
At the cell level, L-Carnitine research looks at how the compound shuttles fatty acids into mitochondria — the energy-producing parts of the cell — for breakdown into usable energy.
Injectable L-Carnitine delivers the compound directly to circulation, bypassing the limitations of intestinal absorption. This provides immediate availability for fatty acid transport into mitochondria. IV/IM routes are preferred in clinical settings for carnitine deficiency and dialysis patients.
Pharmacokinetics
This chart plots how a research dose of L-Carnitine is absorbed and cleared over time — its multi-day clearance curve reflects data from the FDA-approved injectable medication's label.
- Peak
- 3.5 hr
- Half-life
- 17 hrs
- Cleared
- ~84 hrs
FDA Carnitor Label
Research applications
This section lists the research areas — metabolic and cardiovascular research chief among them — that scientists have studied for L-Carnitine, including its FDA-approved use for carnitine deficiency; research-grade material sold here is intended for laboratory study only, not human use.
Metabolic
FDA-approved indication for primary and secondary carnitine deficiency. Injectable form provides 100% bioavailability for rapid repletion of carnitine stores. FDA-approved for end-stage renal disease patients on hemodialysis (standard protocol 10-20 mg/kg post-dialysis). Direct delivery supports enhanced fatty acid oxidation and energy production, particularly beneficial when combined with exercise protocols.
Cardiovascular
Meta-analysis found L-Carnitine associated with 27% reduction in all-cause mortality, 65% reduction in ventricular arrhythmias, and 40% reduction in angina development in acute myocardial infarction patients.
Recovery
L-Carnitine L-Tartrate supplementation improved perceived recovery and soreness and lowered serum creatine kinase following high-volume exercise challenge.
Dosage reference
- Doses used in research
- 500–1000 mg
- Frequency in studies
- 2-3x weekly
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Immediate availability; metabolic effects within days
- Storage
- Room temperature unopened; refrigerate after opening
- Cycle length
- Ongoing for deficiency; 8-12 weeks for performance
- Break between cycles
- Not typically required
Interactions
This list shows which other metabolic-research compounds are studied alongside L-Carnitine, and flags one pairing (thyroid hormone) that calls for extra caution.
Reconstitution & storage
L-Carnitine injectable typically arrives as a ready-to-use sterile solution rather than a powder that needs mixing, so this section covers handling and clarity checks instead of a reconstitution procedure.
- L-Carnitine injectable typically comes pre-mixed as a sterile solution
- Check solution clarity - should be clear and colorless
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Room temperature, use within Per manufacturer expiry (unopened)
Reconstituted: 2-6°C, use within Refrigerate after opening
Quality indicators
These are the visual and documentation checks researchers use to confirm an L-Carnitine sample is pure and properly packaged before it goes into a study.
Clear, Colorless Solution - Injectable L-Carnitine should be a clear, colorless to slightly yellow solution with no particles or cloudiness.
Proper Packaging - Should come in sealed sterile vials with proper pharmaceutical labeling, lot number, and expiration date.
Slight Yellow Tint - A very slight yellow color may be acceptable but check manufacturer specifications. Solution should still be clear.
Cloudy or Particulate - Any cloudiness, particles, or precipitates indicate contamination or degradation - do not use.
Damaged Seal - Never use vials with compromised seals or visible damage. Sterility cannot be assured.
What to expect
This timeline summarizes what the research literature reports at each study stage — research context for comparing studies, not a personal-results promise.
100% bioavailability and rapid tissue distribution
Normalized carnitine levels, potential energy improvements
Enhanced fat utilization during exercise, improved recovery
Sustained metabolic benefits, potential body composition changes
Safety notes
This section summarizes L-Carnitine's regulatory status and handling notes, including its FDA-approved use for carnitine deficiency — reference context for laboratory researchers, not medical guidance.
- Use caution in hypothyroidism - may inhibit thyroid hormone action
- Monitor if on anticoagulants (warfarin) - may enhance effect
- Renal patients should be monitored for TMA/TMAO accumulation
- FDA-approved as Carnitor® for primary and secondary carnitine deficiency and hemodialysis support
Regulatory status
- Approved by the FDA for at least one indication. That approval applies to regulated pharmaceutical products, not to research-grade material.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Comprehensive meta-analysis showing L-Carnitine supplementation significantly decreased body weight (−1.21 kg), BMI (−0.24 kg/m²), and fat mass (−2.08 kg). Non-linear dose-response analysis suggested 2000 mg/day provides maximum effect.
Mayo Clinic meta-analysis found L-Carnitine associated with 27% reduction in all-cause mortality, 65% reduction in ventricular arrhythmias, and 40% reduction in angina development in acute myocardial infarction patients.
L-Carnitine L-Tartrate supplementation for 5 weeks improved perceived recovery and soreness (p=0.021) and lowered serum creatine kinase (p=0.016) following high-volume exercise challenge.